CD4 and Alzheimer disease: To test this hypothesis, we measured chromatin accessibility, NFKB1 binding, and gene expression levels in stimulated CD4+ T cells in subjects with active moderate-to-severe AD as well as in age- and ancestry-matched healthy and non-allergic controls.